Clinical Trial Update: Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating epigenetic modulation in relapsed/refractory follicular lymphoma and marginal zone lymphoma was terminated, with results posted in 2015…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Marginal Zone Lymphoma

Snippet

Sponsor: Duke University | Conditions: Follicular Lymphoma, Marginal Zone Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2015-05-07